NASDAQ:UMRX Cogent Biosciences (UMRX) Stock Price, News & Analysis → Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown” (From Paradigm Press) (Ad) Free UMRX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$8.25▼$8.5950-Day Range$2.35▼$13.0152-Week Range$0.29▼$3.72Volume1.08 million shsAverage Volume1.22 million shsMarket Capitalization$356.31 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsHeadlinesTrendsStock AnalysisCompetitorsHeadlinesTrends Get Cogent Biosciences alerts: Email Address Ad Paradigm PressAfter Conviction, More Bad News for TrumpAs a former advisor to the CIA, the Pentagon and the White House… I feel it’s my duty to warn you about this coming election meltdown.Click here to see the details because this coming election meltdown could trigger… About Cogent Biosciences Stock (NASDAQ:UMRX)Cogent Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The firm's technologies include Antibody-Coupled T-cell Receptor, which is a chimeric protein that binds to tumor targeting antibodies. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Cambridge, MA.Read More Ad Paradigm PressAfter Conviction, More Bad News for TrumpAs a former advisor to the CIA, the Pentagon and the White House… I feel it’s my duty to warn you about this coming election meltdown.Click here to see the details because this coming election meltdown could trigger… UMRX Stock News HeadlinesMay 24, 2024 | msn.comCogent Bio spikes after updating late-stage data for lead assetMay 24, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Ardelyx (ARDX), Cogent Biosciences (COGT) and Immunocore Holdings (IMCR)May 13, 2024 | markets.businessinsider.comBuy Rating on Cogent Biosciences: Financial Stability and Promising Clinical Trials Fuel Positive OutlookMay 10, 2024 | markets.businessinsider.comAnalyst Issues Buy Rating on Cogent Biosciences Amid Clinical and Financial MilestonesMay 7, 2024 | msn.comCogent Biosciences EPS of -$0.62 misses by $0.11May 7, 2024 | investorplace.comCOGT Stock Earnings: Cogent Biosciences Misses EPS for Q1 2024April 24, 2024 | money.usnews.comCogent Biosciences IncFebruary 26, 2024 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Cogent Biosciences (COGT) and Altimmune (ALT)February 26, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Cogent Biosciences (COGT) and Moderna (MRNA)February 26, 2024 | markets.businessinsider.comCogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial ResultsFebruary 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for Cogent Biosciences Ahead of Key Data Presentation on Bezuclastinib with Strong Upside PotentialFebruary 14, 2024 | marketwatch.comCogent Biosciences Stock Soars After $225M Private PlacementFebruary 14, 2024 | msn.comCogent Biosciences announces oversubscribed $225M private placementFebruary 9, 2024 | markets.businessinsider.comBuy Rating on Cogent Biosciences Amid Market Overreaction and Promising Drug ProspectsFebruary 8, 2024 | msn.comCiti starts Cogent Biosciences at buy, cites GI tumor drug potentialDecember 15, 2023 | markets.businessinsider.comBuy Rating Reiterated for Cogent Biosciences as Bezuclastinib Shows Promise in SUMMIT TrialDecember 13, 2023 | markets.businessinsider.comMaintaining Buy on Cogent Biosciences Amid Anticipation of Differentiating Data for BezuclastinibDecember 11, 2023 | markets.businessinsider.comCogent Biosciences Shares Fall Despite Positive Clinical Trial Updates For Systemic Mastocytosis TreatmentDecember 11, 2023 | markets.businessinsider.comDow Surges 100 Points; Cogent Biosciences Shares PlungeDecember 11, 2023 | markets.businessinsider.comCogent Reports Positive Data From Phase 2 APEX Trial Of Bezuclastinib In Systemic MastocytosisDecember 11, 2023 | msn.comCogent slumps after mid-stage data for rare disorder therapyNovember 21, 2023 | markets.businessinsider.comPotential Upside for Cogent Biosciences Due to Imminent Data Readout for Bezuclastinib and Underpriced SharesNovember 14, 2023 | markets.businessinsider.comPromising Clinical Trials and Strong Financial Position Justify Buy Rating for Cogent BiosciencesNovember 4, 2023 | markets.businessinsider.comPromising Clinical Trials and Strong Financial Position Support Buy Rating for Cogent BiosciencesOctober 28, 2023 | markets.businessinsider.comPromising Market Potential for Cogent Biosciences’ Bezuclastinib Spurs Buy RatingSee More Headlines Receive UMRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cogent Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/11/2020Today6/07/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:UMRX CUSIPN/A CIK1622229 Webwww.unumrx.com Phone(617) 945-5576FaxN/AEmployees72Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-31,830,000.00 Net Margins-96.84% Pretax MarginN/A Return on Equity-87.78% Return on Assets-52.14% Debt Debt-to-Equity Ratio0.18 Current Ratio2.90 Quick Ratio2.90 Sales & Book Value Annual Sales$22.50 million Price / Sales15.84 Cash FlowN/A Price / Cash FlowN/A Book Value$1.04 per share Price / Book8.07Miscellaneous Outstanding Shares42,469,000Free FloatN/AMarket Cap$356.31 million OptionableNot Optionable Beta3.93 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesAndrew R. RobbinsPresident, Chief Executive Officer & DirectorGeoffrey HodgeChief Technical Officer & Senior VP-OperationsJohn L. GreenChief Financial & Accounting OfficerJessica SachsChief Medical OfficerGreg MotzHead-ResearchKey CompetitorsAvadel PharmaceuticalsNASDAQ:AVDLArcus BiosciencesNYSE:RCUSLigand PharmaceuticalsNASDAQ:LGNDBelite BioNASDAQ:BLTEXencorNASDAQ:XNCRView All Competitors UMRX Stock Analysis - Frequently Asked Questions How were Cogent Biosciences' earnings last quarter? Cogent Biosciences, Inc. (NASDAQ:UMRX) posted its quarterly earnings results on Tuesday, August, 11th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.21) by $0.03. The company had revenue of $0.53 million for the quarter. Cogent Biosciences had a negative trailing twelve-month return on equity of 87.78% and a negative net margin of 96.84%. What other stocks do shareholders of Cogent Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cogent Biosciences investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Bionano Genomics (BNGO), Pennsylvania Real Estate Investment Trust (PEI), CNBX Pharmaceuticals (CNBX), KushCo (KSHB), Novan (NOVN), Aeterna Zentaris (AEZS) and Zosano Pharma (ZSAN). When did Cogent Biosciences IPO? Cogent Biosciences (UMRX) raised $75 million in an initial public offering on Thursday, March 29th 2018. The company issued 5,800,000 shares at a price of $12.00-$14.00 per share. Morgan Stanley and Cowen served as the underwriters for the IPO and SunTrust Robinson Humphrey and Wedbush Securities were co-managers. This page (NASDAQ:UMRX) was last updated on 6/8/2024 by MarketBeat.com Staff From Our PartnersCollapse of the Petrodollar The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredShocking $16T Elon Musk Crypto LeakReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto mark...Crypto 101 Media | SponsoredSecret energy grid to power millions of homesThis high-security, secret U.S. facility has 2,100 engineers, machinists, and technicians building a new type ...Porter & Company | SponsoredMillionaire-Making “Wealth Pattern” Just Repeated on April 22If you think you missed out on the Bitcoin band wagon… You need to watch this immediately.Paradigm Press | SponsoredBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is cu...Augury Research | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cogent Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cogent Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.